RxDoctor Payments Data

Pramila Nathan, MD

Child & Adolescent Psychiatry · Milford, CTNPI 1366441933

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 39.4% of the total. Reporting peaked in 2019 at $239 and has fallen 62.6% since, to $89 in 2024.

$906in general payments, 2019–2025

Across 44 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$357
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$134
  • Ironshore Pharmaceuticals Inc.$98
  • Lundbeck LLC$77
  • Tris Pharma Inc$61
  • Johnson & Johnson$51
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$82992%
  • Education$778%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$906 in reported general payments places this provider in the 80th percentile of 71 child & adolescent psychiatry providers in Connecticut.

See all child & adolescent psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$15,554
Medicare patients
39
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$20,485
Methylphenidate Hcl27$929
Alprazolam50$621
Escitalopram Oxalate27$514
Lorazepam31$339
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$269
Paroxetine Hcl14$260
Clonazepam16$180
Citalopram HbrCitalopram Hydrobromide14$171
Gabapentin11$163
Lamotrigine14$138
Trazodone Hcl21$136
Duloxetine Hcl16$131
Quetiapine Fumarate17$120
Sertraline Hcl13$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$17$20,48512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 71 child & adolescent psychiatry providers in Connecticut.

Other child & adolescent psychiatry in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →